15.11.26

Hepatorenal Syndrome: Line of Treatment

 

Pharmacological treatment of HRS-AKI primarily aims to reverse the circulatory abnormalities responsible for renal vasoconstriction.

Hepatorenal Syndrome: Line of Treatment
 The main therapeutic strategy involves the administration of vasoconstrictor medications combined with intravenous albumin.

Vasoconstrictors improve effective arterial circulation by increasing systemic vascular resistance and mean arterial pressure (MAP). Albumin supports intravascular volume expansion and improves circulatory function when appropriately administered.

The 2024 ADQI–ICA consensus recommends initiating vasoconstrictor treatment, preferably terlipressin, together with 20–25% albumin immediately after establishing the diagnosis of HRS-AKI.

Terlipressin

Preferred first-line treatment

Terlipressin is a synthetic vasopressin analogue with predominantly V1 receptor-mediated vasoconstrictor activity. It is the preferred pharmacological agent for HRS-AKI in many contemporary treatment protocols.

Mechanism of action

Terlipressin acts primarily on vascular V1 receptors, producing vasoconstriction in the splanchnic circulation.

Its effects include:

  • Reduction in splanchnic vasodilation.
  • Increased systemic vascular resistance.
  • Improvement in effective arterial blood volume.
  • Increased mean arterial pressure.
  • Improved renal perfusion.
  • Potential recovery of glomerular filtration.

.Adverse effects

Potential adverse effects include:

  • Abdominal pain.
  • Diarrhea.
  • Nausea and vomiting.
  • Peripheral ischemia.
  • Cardiac ischemia.
  • Bradycardia.
  • Respiratory complications.

Patients should undergo assessment of oxygenation and volume status before treatment. Continuous pulse oximetry and regular clinical monitoring are recommended during therapy.

Terlipressin should not be initiated in patients experiencing hypoxia or worsening respiratory symptoms. It is also contraindicated in patients with ongoing coronary, peripheral, or mesenteric ischemia under the current US prescribing information.

Particular caution is required in patients with volume overload and severe acute-on-chronic liver failure.

Intravenous albumin infusion

Human serum albumin

Albumin is an essential component of HRS-AKI treatment and is administered in combination with vasoconstrictor therapy.

Mechanism of action

Albumin is a plasma protein that contributes to the maintenance of oncotic pressure and intravascular volume.

Its therapeutic effects include:

  • Expansion of effective circulating volume.
  • Improvement in arterial filling.
  • Support of systemic hemodynamic stability.
  • Potential modulation of inflammatory and oxidative stress pathways.

Recommended administration

A commonly used treatment regimen is:

  • Albumin 20–25% intravenously.
  • Approximately 20–40 g daily during vasoconstrictor treatment, adjusted according to volume status and clinical response.

Monitoring

Patients receiving albumin require monitoring for:

  • Pulmonary edema.
  • Respiratory distress.
  • Peripheral edema.
  • Increased oxygen requirements.
  • Signs of intravascular volume overload.

Albumin administration should be reduced or stopped when volume overload develops.

Norepinephrine

Norepinephrine is an alternative vasoconstrictor that can be used in patients with HRS-AKI, particularly when terlipressin is unavailable or unsuitable.

Mechanism of action

Norepinephrine is an alpha-adrenergic agonist with additional beta-adrenergic activity.

It increases systemic vascular resistance through peripheral vasoconstriction and improves mean arterial pressure.

This can improve effective arterial circulation and renal perfusion.

Adverse effects

  • Cardiac arrhythmias.
  • Peripheral ischemia.
  • Hypertension.
  • Myocardial ischemia.
  • Extravasation-related tissue injury.

Norepinephrine is a useful alternative when terlipressin cannot be used, but it requires close hemodynamic monitoring.

Midodrine and octreotide combination

Midodrine

An oral alpha-1 adrenergic agonist that increases peripheral vascular resistance and supports arterial blood pressure.

Octreotide

A somatostatin analogue that reduces the release of vasodilatory gastrointestinal peptides and helps reduce splanchnic blood flow.

The combination of midodrine and octreotide, together with albumin, has historically been used as an alternative treatment for HRS.

Mechanism of action

Midodrine increases systemic vascular resistance through alpha-1 receptor stimulation.

Octreotide inhibits the release of certain vasodilatory gastrointestinal hormones and reduces splanchnic vasodilation.

Limitations

The midodrine–octreotide combination is generally less effective than terlipressin or norepinephrine in reversing HRS-AKI.

It is therefore usually reserved for situations where preferred vasoconstrictor treatments are unavailable or unsuitable.

Comparison of pharmacological treatments

Treatment Main mechanism                 Clinical role

Terlipressin       V1-mediated vasoconstriction            Preferred first-line agent

Norepinephrine                                                             Alpha-adrenergic vasoconstriction    Alternative first-line option

Midodrine         Alpha-1 receptor stimulation               Alternative treatment

Octreotide        Reduces splanchnic vasodilatory activity     Used with midodrine

Albumin            Supports intravascular volume           Used with vasoconstrictors

Recommended treatment protocol

The following provides a practical overview of the treatment pathway for HRS-AKI.

Clinical treatment pathway for HRS-AKI

Step 1: Suspect HRS-AKI

Cirrhosis of the liver with ascites and deteriorating kidney function.

Step 2: Assess and investigate

Evaluate volume status, infection, bleeding, medications, and alternative causes of AKI.

Step 3: Correct precipitating factors

Treat infection, address bleeding, stop nephrotoxins, and provide appropriate volume resuscitation.

Step 4: Initiate specific therapy

Initiate with Terlipressin plus 20–25% albumin, or norepinephrine plus albumin when appropriate.

Step 5: Monitor response

Monitor serum creatinine, urine output, MAP, oxygen saturation, and volume status.

Response

Continue treatment according to protocol and assess transplantation eligibility.

No response

Reassess diagnosis, optimize treatment, consider RRT, and expedite transplant evaluation.

 Monitoring treatment response

Treatment response should be evaluated through serial clinical and laboratory assessments.

Important parameters include:

  • Serum creatinine.
  • Urine output.
  • Mean arterial pressure.
  • Serum sodium and potassium.
  • Fluid balance.
  • Oxygen saturation.
  • Signs of pulmonary edema.
  • Evidence of ischemic complications.

An increase in MAP and a reduction in serum creatinine are important indicators of therapeutic response.

According to the 2024 ADQI–ICA consensus, terlipressin may be escalated if serum creatinine has not decreased by approximately 25% from baseline after 24 hours, according to the relevant treatment protocol.

Treatment should generally be discontinued when renal function returns close to baseline, severe adverse effects develop, there is no improvement after 48 hours on maximum tolerated doses, renal replacement therapy becomes necessary, or 14 days of treatment have been reached.

 Clinical guidelines and recommendations

Several professional organizations provide recommendations for the diagnosis and management of HRS.

The updated joint consensus emphasizes:

  • Early identification of AKI using contemporary KDIGO-based criteria.
  • Recognition of HRS-AKI without unnecessary delays.
  • Avoidance of a mandatory 48-hour albumin challenge before diagnosis.
  • Early initiation of terlipressin with 20–25% albumin.
  • Individualized albumin dosing based on volume status.
  • Monitoring for respiratory and ischemic complications.
  • Liver transplantation as definitive treatment.

B. American Association for the Study of Liver Diseases (AASLD)

AASLD guidance emphasizes early identification of AKI in cirrhosis, assessment of precipitating factors, appropriate albumin administration, and vasoconstrictor therapy.

Terlipressin is an important treatment option for eligible patients, with norepinephrine considered when terlipressin is unavailable or unsuitable.

C. European Association for the Study of the Liver (EASL)

EASL recommendations emphasize the importance of managing complications of decompensated cirrhosis, treating precipitating infections, restoring circulatory function, and evaluating patients for liver transplantation.

 Important clinical considerations

Despite improvements in pharmacological treatment, HRS remains a serious condition.

Vasoconstrictor treatment may reverse renal dysfunction in some patients, but it does not correct the underlying liver disease.

Moreover, treatment response does not necessarily translate into improved long-term survival unless the underlying hepatic condition is addressed.

Therefore, early transplant evaluation should occur alongside medical treatment rather than being delayed until pharmacological therapy fails.

Conclusion

Hepatorenal syndrome is a severe and potentially life-threatening complication of advanced liver disease, particularly decompensated cirrhosis with ascites. It develops primarily due to complex circulatory disturbances involving portal hypertension, splanchnic vasodilation, reduced effective arterial blood volume, activation of neurohormonal systems, and progressive renal vasoconstriction.

Although HRS was traditionally considered a functional form of renal impairment, contemporary research demonstrates that systemic inflammation, endothelial dysfunction, and structural kidney injury may also contribute to its development.

Early recognition is essential because HRS-AKI can progress rapidly and is associated with substantial morbidity and mortality. Diagnosis requires careful clinical assessment, evaluation of renal function, identification of precipitating factors, and exclusion of alternative causes of kidney dysfunction.

Supportive management, including infection control, electrolyte correction, nutritional optimization, fluid management, and renal replacement therapy when indicated, plays an important role in improving clinical outcomes.

Ultimately, successful management depends on early diagnosis, timely initiation of evidence-based treatment, careful monitoring for complications, and multidisciplinary coordination. Improved awareness of contemporary diagnostic criteria and treatment recommendations can help healthcare professionals recognize HRS earlier, initiate appropriate interventions, and improve patient outcomes.

Medical Disclaimer: The information provided in this article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any medical decisions or starting, changing, or stopping any treatment. Do not ignore or delay seeking medical advice based on information published on this blog.

 

                                                           


 

14.11.26

Hepatorenal Syndrome: Management

The management of Hepatorenal Syndrome (HRS) requires a multidisciplinary approach involving hepatologists, nephrologists, intensivists, and liver transplantation specialists.

Hepatorenal Syndrome: Management
 The primary objectives of treatment are:

  1. Identification and correction of precipitating factors.
  2. Restoration of effective arterial blood volume.
  3. Improvement of renal perfusion and glomerular filtration.
  4. Prevention of further hepatic and renal deterioration.
  5. Management of complications associated with advanced liver disease.
  6. Evaluation for definitive treatment through liver transplantation.

General supportive management

Patients with suspected HRS-AKI generally require hospital admission, particularly when renal dysfunction is progressive or associated with infection, electrolyte disturbances, or hemodynamic instability.

Initial management includes:

  • Frequent monitoring of blood pressure, heart rate, and oxygen saturation.
  • Strict monitoring of fluid intake and urine output.
  • Daily assessment of body weight and fluid balance.
  • Serial measurement of serum creatinine, urea, electrolytes, and liver function.
  • Assessment of volume status and signs of pulmonary congestion.
  • Identification and treatment of infection.
  • Review of all prescribed medications.

The patient's hemodynamic status should be carefully assessed to determine whether intravascular volume expansion is necessary.

General supportive management

Patients with suspected HRS-AKI generally require hospital admission, particularly when renal dysfunction is progressive or associated with infection, electrolyte disturbances, or hemodynamic instability.

Initial management includes:

  • Frequent monitoring of blood pressure, heart rate, and oxygen saturation.
  • Strict monitoring of fluid intake and urine output.
  • Daily assessment of body weight and fluid balance.
  • Serial measurement of serum creatinine, urea, electrolytes, and liver function.
  • Assessment of volume status and signs of pulmonary congestion.
  • Identification and treatment of infection.
  • Review of all prescribed medications.

The patient's hemodynamic status should be carefully assessed to determine whether intravascular volume expansion is necessary.

Discontinuation of precipitating medications

Certain medications can worsen renal perfusion and aggravate kidney dysfunction in patients with cirrhosis.

The following medications should generally be withheld during suspected HRS-AKI, depending on the clinical situation:

  • NSAIDs, such as ibuprofen and diclofenac.
  • Nephrotoxic antibiotics, particularly aminoglycosides, where alternatives are available.
  • Diuretics when volume depletion or AKI is present.
  • ACE inhibitors and angiotensin receptor blockers.
  • Other medications that may contribute to hypotension or renal impairment.

Diuretic therapy should be reassessed according to the patient's volume status rather than discontinued automatically in every patient.

Management of infections

Infections are important precipitating factors for HRS and should be identified and treated promptly.

Spontaneous bacterial peritonitis is particularly significant in patients with cirrhosis and ascites.

Management includes:

  • Diagnostic paracentesis when SBP is suspected.
  • Ascitic fluid neutrophil count and culture.
  • Prompt administration of appropriate empirical antibiotics.
  • Subsequent modification of antibiotic therapy according to culture results and local resistance patterns.
  • Albumin administration in appropriate patients with SBP to reduce the risk of renal impairment.

In patients with SBP, intravenous albumin is commonly administered at 1.5 g/kg on day 1 and 1 g/kg on day 3, with appropriate clinical assessment.

Fluid and electrolyte management

Fluid management is a critical component of HRS treatment.

Although patients may have significant ascites and peripheral edema, their effective arterial blood volume may be reduced.

Therefore, treatment must distinguish between intravascular depletion and total-body fluid overload.

Important measures include:

  • Avoidance of excessive fluid restriction or inappropriate fluid administration.
  • Careful correction of hyponatremia.
  • Monitoring and correction of potassium abnormalities.
  • Avoidance of unnecessary sodium loading.
  • Management of pulmonary congestion and peripheral edema.
  • Individualized albumin administration.

Fluid restriction is generally reserved for selected patients with clinically significant hypervolemic hyponatremia rather than applied routinely to all patients with HRS.

Nutritional management and lifestyle modifications

Nutritional support is important in patients with advanced liver disease because malnutrition and sarcopenia are common and may worsen clinical outcomes.

Recommended measures include:

  • Adequate caloric intake.
  • Sufficient dietary protein, generally around 1.2–1.5 g/kg/day in patients with cirrhosis, adjusted to individual circumstances.
  • Small, frequent meals.
  • A late-evening nutritional snack to reduce prolonged fasting.
  • Avoidance of alcohol.
  • Moderate dietary sodium restriction in patients with ascites, commonly around 2 g of sodium daily.
  • Avoidance of unprescribed herbal preparations and potentially nephrotoxic medications.

Severe protein restriction should generally be avoided, even in patients with hepatic encephalopathy, because it can aggravate malnutrition.

Lifestyle modifications are supportive measures and cannot reverse established HRS without appropriate medical treatment.

Management of ascites

Ascites is commonly associated with HRS and may require therapeutic intervention.

Large-volume paracentesis can be performed in patients with tense or refractory ascites.

When more than 5 litres of ascetic fluid are removed, albumin replacement is generally recommended, commonly at 6–8 g per litre of fluid removed.

This reduces the risk of post-paracentesis circulatory dysfunction.

Renal replacement therapy

Renal replacement therapy (RRT), including hemodialysis and continuous renal replacement therapy (CRRT), may be required in patients with severe renal dysfunction or complications that cannot be adequately controlled with medical treatment.

Indications include:

  • Refractory hyperkalemia.
  • Severe metabolic acidosis.
  • Pulmonary edema or refractory fluid overload.
  • Uremic complications.
  • Certain cases of severe electrolyte imbalance.

CRRT may be preferred in hemodynamically unstable patients because it allows gradual fluid and solute removal.

However, dialysis does not correct the underlying hepatic circulatory abnormalities responsible for HRS. It is generally considered a supportive or bridging intervention, particularly in patients awaiting liver transplantation.

Liver transplantation

Definitive treatment

Liver transplantation is the most effective definitive treatment for eligible patients with advanced liver disease complicated by HRS.

It corrects the underlying hepatic dysfunction and portal hypertensive circulatory abnormalities responsible for renal vasoconstriction.

Following successful transplantation, renal perfusion and kidney function may improve substantially.

However, the extent of renal recovery depends on several factors, including:

  • Duration of HRS.
  • Severity of pre-existing renal dysfunction.
  • Presence of structural kidney injury.
  • Patient age and comorbidities.
  • Severity of hepatic decompensation.
  • Duration of renal replacement therapy, if required.

Some patients experience complete renal recovery following liver transplantation, whereas others may continue to have impaired renal function.

Combined liver kidney transplantation may be considered in selected patients with significant irreversible or prolonged renal dysfunction, according to established transplant eligibility criteria.

Prognosis and follow-up

HRS is associated with poor prognosis, particularly when diagnosis and treatment are delayed.

The prognosis depends on the severity of liver disease, response to vasoconstrictor therapy, presence of infection, and availability of liver transplantation.

Regular follow-up is essential for monitoring:

  • Renal function.
  • Electrolyte balance.
  • Nutritional status.
  • Ascites and fluid retention.
  • Recurrence of infection.
  • Response to treatment.
  • Liver transplantation eligibility.

 Medical Disclaimer: The information provided in this article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any medical decisions or starting, changing, or stopping any treatment. Do not ignore or delay seeking medical advice based on information published on this blog.

                                                                                                      


13.11.26

Hepatorenal Syndrome: Signs, Symptoms, and Diagnosis


 Hepatorenal Syndrome (HRS) generally develops in patients with advanced liver disease and may present with gradual or rapidly progressive deterioration in renal function.

The clinical manifestations are related to both hepatic decompensation and impaired kidney function.

 

Hepatorenal Syndrome: Signs, Symptoms, and Diagnosis
4.1 Clinical signs and symptoms

1. Oliguria

Oliguria is a common manifestation of significant renal dysfunction and refers to reduced urine output. It may occur because of decreased renal perfusion and reduced GFR.

However, oliguria is not essential for diagnosing HRS-AKI, as serum creatinine changes may precede substantial reductions in urine output.

2. Ascites

Ascites is the accumulation of fluid within the peritoneal cavity. It results from portal hypertension, sodium retention, and increased fluid movement into the abdominal cavity.

Patients with HRS frequently have severe or refractory ascites.

3. Peripheral edema

Fluid retention may cause bilateral lower-limb edema, particularly in patients with advanced hepatic dysfunction and hypoalbuminemia.

4. Fatigue and generalized weakness

Patients may experience persistent fatigue, reduced physical activity, and generalized weakness due to hepatic dysfunction, renal impairment, electrolyte disturbances, and systemic inflammation.

5. Jaundice

Jaundice occurs because of impaired hepatic bilirubin metabolism and excretion. It is a common feature of advanced liver disease but is not specific to HRS.

6. Hepatic encephalopathy

Patients may develop confusion, altered consciousness, disorientation, and, in severe cases, coma due to impaired hepatic detoxification and accumulation of neurotoxic substances.

7. Fluid overload and respiratory symptoms

Severe sodium and water retention may cause pulmonary congestion, pleural effusions, and respiratory difficulty, particularly when renal dysfunction is advanced.

4.2 Laboratory findings

Laboratory investigations play an important role in evaluating renal dysfunction, identifying precipitating conditions, and excluding alternative causes.

Investigation    Typical findings or significance

Serum creatinine    Increased

Blood urea nitrogen                Frequently increased

Estimated GFR        Reduced, although creatinine-based estimates may be inaccurate in cirrhosis

Serum sodium         May be reduced due to dilutional hyponatremia

Serum potassium    May be increased, particularly in advanced renal dysfunction

Serum albumin       Frequently reduced due to impaired hepatic synthesis and other factors

Serum bilirubin       Often elevated due to hepatic dysfunction

Urinalysis                 May be relatively bland, although abnormalities do not exclude HRS

Urine sodium           Frequently low, but not reliable as a standalone diagnostic test

Urine osmolality      May be relatively high because of ADH-mediated water retention

It is important to recognize that serum creatinine may underestimate the severity of renal dysfunction in patients with cirrhosis because of reduced muscle mass, impaired hepatic creatine synthesis, and altered creatinine production.

4.3 Diagnostic criteria for HRS-AKI

The 2024 joint consensus recommendations of the Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) provide updated diagnostic criteria for HRS-AKI.

The diagnosis requires the following:

1. Underlying cirrhosis with ascites.

2. Evidence of acute kidney injury, defined by one or both of the following:

  • Increase in serum creatinine of at least 0.3 mg/dL (26.5 µmol/L) within 48 hours.
  • Increase in serum creatinine of at least 50% from baseline, known or presumed to have occurred within the preceding seven days.

Alternatively, urine output of 0.5 mL/kg/hour or less for at least six hours may establish AKI.

3. No improvement in serum creatinine and/or urine output within 24 hours following adequate volume resuscitation, when clinically indicated.

4. Absence of strong evidence for an alternative explanation as the primary cause of AKI.

An important change in the 2024 consensus is that a mandatory 48-hour albumin administration period is no longer required before diagnosing HRS-AKI. This helps avoid unnecessary delays in treatment and prevents inappropriate albumin administration in patients who are already volume overloaded.

4.4 Classification of HRS

Contemporary terminology classifies HRS according to the duration and nature of kidney dysfunction.

Classification    Description

HRS-AKI               Hepatorenal syndrome associated with acute kidney injury

HRS-AKD             Hepatorenal syndrome associated with acute kidney disease lasting less than 90 days

HRS-CKD             Hepatorenal syndrome associated with chronic kidney disease lasting more than 90 days

The previous type 1 and type 2 classifications are largely historical and have been replaced by this newer framework.

4.5 Differential diagnosis

HRS must be differentiated from other causes of renal dysfunction in patients with liver disease.

Important differential diagnoses include:

  • Acute tubular injury or necrosis.
  • Pre-renal AKI due to dehydration or hemorrhage.
  • Sepsis-associated AKI.
  • Drug-induced nephrotoxicity.
  • Glomerulonephritis.
  • Acute interstitial nephritis.
  • Urinary tract obstruction.
  • Pre-existing chronic kidney disease.

Urinalysis, urine microscopy, renal ultrasonography, clinical assessment, and selected kidney injury biomarkers may help distinguish these conditions.

However, HRS can coexist with tubular injury or chronic kidney disease; therefore, the presence of some structural abnormalities does not automatically exclude HRS.

4.6 Additional investigations

The following investigations may be useful:

  • Complete blood count to identify infection, anemia, and thrombocytopenia.
  • Liver function tests to assess hepatic impairment.
  • Coagulation profile, particularly prothrombin time and INR.
  • Blood and urine cultures when infection is suspected.
  • Diagnostic paracentesis to evaluate for spontaneous bacterial peritonitis.
  • Renal ultrasonography to exclude obstruction and assess renal anatomy.
  • Electrocardiography when electrolyte disturbances are suspected.
  • Chest radiography and oxygenation assessment when fluid overload or respiratory complications are present.

Clinical importance: Early identification of HRS-AKI is particularly important because treatment response is generally more favorable when therapy is initiated before severe and prolonged renal impairment develops.

Medical Disclaimer: The information provided in this article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any medical decisions or starting, changing, or stopping any treatment. Do not ignore or delay seeking medical advice based on information published on this blog.

                                                                    


CONTINUE READING

 Hepatorenal Syndrome: Management

 

12.11.26

Hepatorenal Syndrome: Causes and Risk Factors


HRS generally develops in patients with severe hepatic dysfunction and circulatory disturbances. Although advanced cirrhosis is the most common underlying condition, several other hepatic disorders and clinical complications may contribute to its development.

Hepatorenal Syndrome: Causes and Risk Factors

  3. Causes and Risk Factors of Hepatorenal Syndrome

HRS generally develops in patients with severe hepatic dysfunction and circulatory disturbances. Although advanced cirrhosis is the most common underlying condition, several other hepatic disorders and clinical complications may contribute to its development.

3.1 Cirrhosis

Cirrhosis is the leading cause of HRS. It is characterized by progressive hepatic fibrosis, regenerative nodule formation, and distortion of the normal hepatic vascular architecture.

These changes increase intrahepatic vascular resistance and produce portal hypertension.

As cirrhosis progresses, patients develop complications such as:

  • Ascites.
  • Portal hypertension.
  • Esophageal and gastric varices.
  • Hepatic encephalopathy.
  • Spontaneous bacterial peritonitis.
  • Coagulopathy.
  • Progressive hepatic dysfunction.

The presence of ascites, particularly refractory ascites, indicates advanced circulatory dysfunction and increases the likelihood of developing HRS.

3.2 Acute liver failure

Acute liver failure is characterized by rapid deterioration of hepatic function in a patient without pre-existing cirrhosis, generally accompanied by coagulopathy and hepatic encephalopathy.

Although HRS is classically associated with cirrhosis and ascites, severe acute liver failure can also cause renal dysfunction through systemic inflammation, hemodynamic instability, endothelial dysfunction, and impaired renal perfusion.

It is important to distinguish HRS-like renal dysfunction in acute liver failure from formally defined HRS-AKI, whose contemporary diagnostic criteria require cirrhosis with ascites.

3.3 Viral hepatitis

Chronic viral hepatitis, particularly hepatitis B and hepatitis C, can lead to progressive hepatic inflammation, fibrosis, and cirrhosis.

Patients with advanced viral hepatitis-related cirrhosis are at increased risk of developing HRS, especially when complicated by portal hypertension, ascites, or infection.

3.4 Alcohol-associated liver disease

Long-term excessive alcohol consumption can cause alcoholic hepatitis, hepatic steatosis, fibrosis, and cirrhosis.

Severe alcohol-associated hepatitis may produce systemic inflammation and circulatory disturbances, increasing susceptibility to acute kidney injury and HRS.

3.5 Metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD), particularly its progressive inflammatory form, can cause advanced fibrosis and cirrhosis.

Patients with decompensated MASLD-related cirrhosis may develop HRS through the same portal hypertensive and circulatory mechanisms observed in other forms of cirrhosis.

3.6 Other contributing conditions

Other liver diseases that may eventually result in advanced cirrhosis and predispose patients to HRS include:

  • Autoimmune hepatitis.
  • Primary biliary cholangitis.
  • Primary sclerosing cholangitis.
  • Hemochromatosis.
  • Wilson disease.
  • Alpha-1 antitrypsin deficiency.
  • Vascular liver disorders, including Budd–Chiari syndrome.

3.7 Precipitating factors

·         Several clinical events can trigger HRS in patients with advanced liver disease.

·         A. Spontaneous bacterial peritonitis

·         SBP is a major precipitating factor. Infection triggers systemic inflammation and worsens circulatory dysfunction, potentially resulting in acute renal impairment.

·         B. Gastrointestinal bleeding

·         Bleeding from esophageal varices or other gastrointestinal sources causes intravascular volume depletion and reduced renal perfusion.

·         C. Excessive diuretic therapy

·         Overuse of diuretics can result in intravascular volume depletion, electrolyte disturbances, and worsening renal perfusion.

·         D. Large-volume paracentesis without adequate albumin replacement

·         Removal of large amounts of ascitic fluid without appropriate albumin replacement can produce post-paracentesis circulatory dysfunction and increase the risk of renal impairment.

·         E. Severe dehydration

·         Vomiting, diarrhea, poor oral intake, and inadequate fluid replacement may reduce circulating blood volume and precipitate AKI.

·         F. Nephrotoxic medications

·         Non-steroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, and other nephrotoxic agents can aggravate renal dysfunction in patients with cirrhosis.

·         G. Severe hepatic decompensation

·         Acute-on-chronic liver failure (ACLF), severe alcoholic hepatitis, and advanced portal hypertension are associated with increased systemic inflammation and circulatory instability.

3.8 Major risk factors

Risk factor                          Mechanism contributing to HRS

Advanced cirrhosis                       Severe portal hypertension and circulatory dysfunction

Refractory ascites                          Persistent sodium retention and arterial underfilling

Spontaneous bacterial peritonitis Systemic inflammation and hemodynamic deterioration

Gastrointestinal bleeding             Reduced circulating blood volume

Hyponatremia                                Marker of advanced circulatory dysfunction

Excessive diuretic use                 Intravascular volume depletion

Large-volume paracentesis         Post-paracentesis circulatory dysfunction

Nephrotoxic medications             Additional renal injury

Acute-on-chronic liver failure     severe systemic inflammation and organ dysfunction

Early identification and correction of these precipitating factors are essential to prevent progression to severe renal dysfunction.

 Medical Disclaimer: The information provided in this article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any medical decisions or starting, changing, or stopping any treatment. Do not ignore or delay seeking medical advice based on information published on this blog.

 

                                                                


 

Continue Reading

 Hepatorenal Syndrome: Signs, Symptoms, and Diagnosis

 

Hepatorenal Syndrome: Line of Treatment

  Pharmacological treatment of HRS-AKI primarily aims to reverse the circulatory abnormalities responsible for renal vasoconstriction.  T...